


VOLUME : 27
NUMBER : 02
APRIL - JUNE , 2017

ISSN 1560 - 9014 - PRINT
ISSN 2413 - 7650 - ONLINE



JPAD

www.jpada.org.pk

Journal of Pakistan Association of Dermatologists

A Publication of:
PAKISTAN ASSOCIATION OF DERMATOLOGISTS

Journal of Pakistan Association of Dermatologists

Volume 27, Number 2 April-June, 2017

Editor-in-Chief

Tahir Saeed Haroon

Editor

Ijaz Hussain

Associate Editors

Farhana Muzaffar

Zahida Rani

Faria Asad

Publication Manager

Abdul Hameed

Editorial Board

Amer Ejaz

Arfan ul Bari

Asher Ahmad Mashhood

Azim Jahangir Khan

Doulat Rai Bajaj

Ghulam Mujtaba

Ijaz Ahmad

Jamil Ahmad Shaheen

Mahmood Noor

Mansoor Dilnawaz

Muhammad Khalid

Naeem Raza

Naseema Kapadia

Pakistan

Nasser Rashid Dar

Shahbaz Aman

Shahbaz Janjua

Shahid Jawaaid Akhtar

Syed Dilawar Abbas Rizvi

Syed Shamsuddin

Rehanuddin

Tahir Jamil Ahmad

Tariq Rashid

Yasmeena Khan

Zafar Iqbal Sheikh

Overseas

Aisha Sethi (USA)

Ayyaz Shah (USA)

Ian McColl (Australia)

Imtiaz Ahmad (UK)

Jyakar Thomas (India)

Khalid Al Aboud (KSA)

MR Namazi (Iran)

JPAD, the official journal of Pakistan Association of Dermatologists is published quarterly, four issues per volume and one volume per year (ISSN 1560-9014, print; ISSN 2413-7650, online). The journal is recognized by Pakistan Medical and Dental Council and is indexed in College of Physicians and Surgeons Pakistan MEDLIP; Ulrich's International Periodical Directory, USA; ExtraMED, London; EMBASE/Excerpta Medica, PakMediNet, The Netherlands; and Index Medicus, WHO Alexandria, Egypt.

Subscription

A complimentary copy of the journal is provided to all PAD members. Subscription rates per volume are Rs. 4000.00 for Pakistan, £80.00 for UK and \$120.00 for US and the rest of world.

Copyright

© 2017 Any material published in JPAD is copyright of Pakistan Association of Dermatologists.

Journal of Pakistan Association of Dermatologists

Volume 27, Number 2 April-June, 2017

Contents

Editorial

- Blended learning: a pedagogical alternative to traditional learning in dermatology 99
Sadia Masood, Naveed Yousuf

Original Articles

- VDR polymorphisms Apal (rs7975232), TaqI (rs731236) and FokI(rs2228570) in Pakistani vitiligo patients and controls 102
Sumaira Sajjad, Saeeda Munir, Simeen-Ber-Rahman, Nusrat Saba, Sadia Rehman
- Efficacy of sclerotherapy with sodium tetradecyl sulphate in the treatment of pyogenic granuloma 110
Rutaba Kiran, Faria Asad, Sohaib Haider, Bushra Bashir, Zahida Rani, Khawar Khurshid, Sabrina Suhail Pal*
- Comparison of efficacy of intralesional 5-fluorouracil plus triamcinolone acetonide versus intralesional triamcinolone acetonide in the treatment of keloids 114
Farah Saleem, Zahida Rani, Bushra Bashir, Faria Altaf, Khawar Khurshid, Sabrina Suhail Pal
- Childhood herpes zoster: a study from tertiary centre 120
Shashikant Malkud, Veeresh Dyavannanavar
- Cutaneous lesions in neonatal intensive care unit in a tertiary care centre 124
Kikkeri Narayanshetty Naveen, Praveen S Bagalkote, Sachin Manohar Shetty, Umesh Dixit*
- Indoleamine 2, 3-dioxygenase (IDO) level in leprosy patients with positive serology 131
Ago Harlim, M. Zen Rahfiludin
- A clinico-demographic profile of 110 male patients with genital ulcer(s) 135
Piyush Kumar, Avijit Mon, Satyendra Nath Chowdhury, Nilay Kanti Das, Pijush Kanti Datta, Ramesh Chandra Gharami
- Changing trend in sexually transmitted infections among males in a tertiary care centre from Eastern India 145
Md. Zeeshan, Abhijeet Kumar Jha, Amit Ranjan, P.K. Roy, S. Mishra, R.K.P. Chaudhary
- Superficial cryotherapy – An effective therapeutic modality for ingrown toenail 149
Naveen Sethi, B.K. Brar, B.B. Mahajan

| | |
|--|-----|
| Histopathological analysis of skin biopsies in a tertiary care setting <i>Faiza Azam, Sidra Munir, Ameena Ashraf, Ambereen Anwar Imran, Tariq Rashid</i> | 154 |
| Cutaneous adverse drug reactions profile in a tertiary care hospital in North India <i>B.K. Brar, Jashandeep Kaur, Sumir Kumar, Naveen Sethi, Raj Kumar</i> | 158 |
| Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1064nm) laser for the treatment of facial melasma in local population <i>Tahir Kamal, Usma Iftikhar</i> | 164 |

Case Reports

| | |
|--|-----|
| Adams-Oliver syndrome: A case report <i>Shehla Shaukat, Ansa Nida Fatima, Muhammad Nadeem, Tahir Jamil Ahmad</i> | 169 |
| Plasmapheresis: an effective treatment in patients of toxic epidermal necrolysis: case report of two patients <i>Maheen Irfan, Nadia Ali Azfar, Lamees Mahmood Malik, Tariq Rashid</i> | 173 |
| Multiple familial trichoepithelioma in mother and daughter <i>Bushra Bashir, Zahida Rani, Rutaba Kiran, Ijaz Hussain</i> | 177 |
| Generalized morphea - a case report <i>Aneela Asghar, Saira Riaz, Tahir Jamil Ahmad</i> | 180 |
| Delayed diagnosis of neural signs of leprosy <i>Mutaher Zia, Muhammad Irfan Anwar</i> | 183 |
| Papillon-Lefevre syndrome: case report <i>Ghasem Rahmatpour Rokni, Tahereh Karimi, Mahnaz Sharifian</i> | 187 |
| Urticaria pigmentosa in a child with sporadic bilateral diffuse conjunctival redness: Case report and review of the literature <i>Ali H. Al-Ghamdi, Ahmed Hassan Al-Ghamdi, Hasan S. Al-Ghamdi, Aziz A. A. Al-Sohaimi, Mesfer Al-Ghamdi</i> | 192 |

PhotoDermDiagnosis

| | |
|--|-----|
| Neurofibromatosis-1 and zosteriform nevus spilus: A very rare clinical coexistence <i>Tasleem Arif, Mohammad Adil, Syed Suhail Amin</i> | 197 |
|--|-----|

Information for authors

200

Indoleamine 2, 3-dioxygenase (IDO) levels in leprosy patients with positive serology

Ago Harlim, M. Zen Rahfiludin*

Faculty of Medicine, The Christian University of Indonesia, Jl. Mayjen Sutoyo. Cawang . Jakarta Timur (50275). Indonesia

* Faculty of Public Health, Diponegoro University, Indonesia
Jl. Prof. Soedarto, Sh, Tembalang, Semarang (50239). Indonesia

Abstract

Background Seropositive leprosy individuals have a tendency to experience a change into leprosy lepromatous type. Previous studies have demonstrated that the activity of indoleamine 2, 3-dioxygenase (IDO) in patients with lepromatous type leprosy is higher than those with tuberculoid type leprosy. However, no study has been available showing how IDO level can be correlated to seropositive subjects.

Methods Our observational cross-sectional study was conducted in Brebes, Central Java, Indonesia. Leprosy seropositivity was determined by measuring the level of anti-phenolic glycolipid-1 IgM and IDO level using ELISA.

Results Result of The IDO level in seropositive leprosy subjects was higher compared to those who were seronegative (p = 0.048).

Conclusion In the early stage of leprosy infection, a high level of IDO level can already be found; therefore, it can affect immune response and ultimately affecting further course of the disease .

Key words

Seropositive leprosy, indoleamine 2, 3-dioxygenase, anti-phenolic glycolipid-1 IgM.

Introduction

Leprosy still remains a major public health problem in Indonesia since the incidence of leprosy is relatively high.¹ It is possibly due to contact with seropositive leprosy patients that have been turning into manifest leprosy.

Measuring the level of anti-phenolic glycolipid-1 immunoglobulin M (PGL-1 IgM) is one of the methods to detect seropositive leprosy subjects.^{2,3} The level of such cellular immune response will determine leprosy spectrum. The

cellular immunity in leprosy tuberculoid type is still good, on the contrary, there is decreased cellular immunity in leprosy lepromatous type.⁴ Individuals with seropositive leprosy contact (IgM anti-PGL-1 level more than 600 unit/ml), have a tendency to experience a change into leprosy lepromatous type.

Previous studies have demonstrated that leprosy patients with lepromatous type have a higher activity of indoleamine 2, 3-dioxygenase (IDO) compared to those with tuberculoid type. The role of IDO levels in leprosy has been studied and an increased number of macrophages/dendritic cells (DC-lineage IDO+ cells were found in lepromatous (LL) compared to tuberculoid (BT) and reversal reaction (RR) patients. LL lesions were characterized by

Address for correspondence

Dr. M. Zen Rahfiludin
Faculty of Public Health,
Universitas of Diponegoro, Jl. Prof Soedarto Sh,
Tembalang. Semarang. Indonesia
Email: rafiludin@yahoo.com

massive macrophage infiltration containing a variable number of Virchow cells, full of bacilli accompanied by few lymphocytes, separated from the flat epidermis by a clear zone. BT lesions were characterized by an organized dermal granuloma composed of phagocytic cells with evident epithelioid differentiation surrounded by lymphocytes of giant cells. RR lesions showed activated macrophages with an epithelioid appearance, organized or not as granuloma.⁵

However, no study has been conducted to evaluate how IDO level can be correlated to seropositive leprosy subjects (IgM anti PGL – 1 level more than 600 unit/ml) and have not showed a clinical manifestation on the skin. Our study aimed to identify the difference of IDO level between seropositive and seronegative leprosy subjects.

Methods

Our study was an observational study using a cross-sectional method. In August 2015, the study was conducted in Brebes, Central Java, Indonesia. Ethical clearance was approved by the Ethics Committee of Medical and Public Health Research, Faculty of Public Health, Diponegoro University.

The eligible subjects participated in our study were those who fulfilled the inclusion criteria: individuals who were living together with a leprosy patient, age between 15-55 years, showed no clinical symptom of leprosy, were not taking immunosuppressants during the last three months prior to the study and those who were willing to participate in our study. They also did not suffer from tuberculosis and did not take any anti-tuberculosis medications. The subjects were divided into 2 groups, i.e. those with seropositive leprosy (anti PGL-1 IgM >

600 unit/mL) 6 and those who were seronegative.

Five milliliters of venous blood was drawn from each subject. The whole blood was centrifuged to separate the serum, which was then stored at – 70°C. Seropositive leprosy was determined by measuring the levels of anti-PGL-1 IgM antibodies using enzyme-linked immunosorbent assay (ELISA) (Polyclonal rabbit anti-human IgM/HRP (Dako ®) and analyzing IDO levels using ELISA commercial kits (Cusabio®, Catalog No: CSB-E09966h). All tests were conducted at the Institute Tropical Disease Laboratory, Airlangga University, Surabaya.

The education level of subjects was categorized into 2 groups, i.e. basic and moderate education. Subjects in basic education group were those who had completed their elementary and junior high school; while moderate education group involved those with senior high school educational background

Results

Table 1 shows that the gender, level of education and age had no effect on the seropositivity (anti-PGL-1 IgM antibodies levels) in leprosy patients; but the levels of IDO were significantly different between seropositive leprosy with seronegative subjects ($p = 0.048$).

In sex variable, there were 20.7% male and 79.3% female with seropositive leprosy and 33.3% male and 66.7% female with seronegative leprosy. There is no significant difference between seropositive leprosy subjects and seronegative leprosy subjects in sex variable ($p = 0.275$).

In level of education variable, seropositive leprosy subjects in primary education is 82.8% and 17.2% is in higher education while in

Table 1 Subject characteristics and indoleamine 2, 3-dioxygenase (IDO) levels.

| Variables | Seropositive leprosy (n=29) | Seronegative leprosy (n =30) | P |
|----------------------------|--------------------------------|---------------------------------|--------------------|
| Sex | | | |
| Male (%) | 20.7 | 33.3 | 0.275 ^a |
| Female (%) | 79.3 | 66.7 | |
| Level of education | | | |
| Primary education (%) | 82.8 | 80.0 | 0.786 ^a |
| Higher education (%) | 17.2 | 20.0 | |
| Age (years), (mean + SD) | 33 ± 10 | 35 ± 11 | 0.399 ^b |
| IDO (pg/mL), (median + SD) | 13.80 ± 9.13 | 9.10 ± 4.60 | 0.048 ^c |

a=chi-square test, b= independent t-test, c=Mann-Whitney test

seronegative leprosy subjects there were 80% in primary education and 20% in higher education ($p = 0.786$)

The mean age of seropositive leprosy subjects was 33 ± 10 years and the mean age of seronegative leprosy subjects was 35 ± 11 years. ($p = 0.399$)

The mean IDO level in seropositive leprosy subject was 13.80 ± 9.13 pg/mL while that in seronegative leprosy subject was 9.10 ± 4.60 pg/mL. There was significant difference between seropositive leprosy and seronegative leprosy subjects in terms of IDO level ($p=0.048$).

Discussion

The first body mechanical defense against *Mycobacterium leprae* is by activating the antigen presenting cells (APCs) of immune system, i.e. the dendritic cells, monocytes and macrophages. IDO is predominantly expressed in APCs. Interferon gamma (IFN- γ) and dependent and/or independent signal pathways can activate and mediate IDO.⁷

Higher level of IDO found in seropositive leprosy subjects of our study supported the results of previous studies which indicate a high IDO protein expression in lepromatous skin lesions and high IDO activity in the sera of lepromatous leprosy patients.⁵ People who live

together under one and the same roof with leprosy patients with seropositive anti-PGL-I antibody have higher risk for developing leprosy (particularly the lepromatous type) compared to those who have contact with seronegative patients. The anti-PGL-I antibody level in people who live together under one and the same roof with leprosy indicates increased risk of having leprosy in the next 4 years. Another study in Philippines showed an increased risk of developing leprosy to 24-fold is caused by seropositive contacts.^{8,9}

In addition due to *M. leprae*, the increased IDO activity in the sera of lepromatous leprosy patients also depends on IFN- γ . There is also a statement that IDO activity was at least partially dependent upon IFN- γ from a study in dengue patients.¹⁰ IDO can be induced in response to various stimuli. The most potent inducer is IFN- γ , although other inflammatory stimuli, including type-I interferons (IFN- α/β) and bacterial lipopolysaccharide (LPS), and some viruses and intracellular pathogens, can induce IDO expression.¹⁵ Support for the “two signal” requirement for IDO-expression has also been obtained in human samples.¹⁴ For example, human monocytes expressed IDO in lepromatous leprosy due to the synergistic actions of IFN- γ and the bacterium (likely through pattern recognition receptor signaling).⁵ *M. leprae* and IFN- γ is a cause of an increased of IDO expression in monocytes leprosy patients lepromatous type.⁵ Leprosy patients with clinical

manifestation of leprosy or those with seronegative leprosy have a less IFN- γ level than seropositive leprosy.¹¹

A higher IDO level in seropositive group found in our study supports the results of some previous studies, which showed that IDO induction after bacterial infection could be beneficial to the host. Amino acid tryptophan will break into stable metabolite called kynurenine when the IDO level increases.¹² Moreover, tryptophan depletion and starvation will occur since bacteria need tryptophan.^{13,14} The growth of bacteria is dependent on the greater amount of tryptophan rather than T cells.¹³

IDO could be considered to be a double-edged sword in the immune response against pathogens. Immune cells, including antigen-presenting cells like DCs, are able to express IDO in response to various stimuli.¹⁰

Acknowledgement

Our grateful thank to Prof. Indropo Agustini, MD, DV and Leprosy Study Group of Tropical Disease Centre for using the laboratory for IgM M anti-PGL-1 and IDO assay test at University of Airlangga, Surabaya. Indonesia and also to the technician of the Institute Tropical Disease (ITD) Laboratory, Iswayudi SKM; Dinar Adriaty, S.Si, M. Kes; Ratna Wahyuni S.Si, M. Kes who examined IgM anti-PGL-1 and IDO.

References

1. World Health Organization (WHO). Global leprosy update, 2013; reducing diseases burden. *Wkly Epidemiol Res.* 2014;**89**:389-400.
2. Agusni I, Adriaty D, Wahyuni R, Izumi S. Correlation between the sero-positivity level and new case detection rate (NCDR) in some leprosy endemic areas of Indonesia. *Jpn J Lepr.* 2009;**78**:140.

3. Izumi S. Subclinical infection by Mycobacterium leprae. *Int J Lepr.* 1999;**67** (4) (Suppl):S67-71.
4. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. *Clin Microbiol Rev.* 2006;**19**:338-81.
5. de Souza Sales J, Lara FA, Amadeu TP, de Oliveira Fulco T, da Costa Nery JA, Sampaio EP *et al.* The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. *Clin Exp Immunol.* 2011;**165**:251-63.
6. Rahfiludin MZ, Pangestuti DR. Phyllanthus niruri extract could improve immunoglobulin-M anti phenolic glycolipid-1 level in seropositive contact of Hansen's disease patients. *J Health Res.* 2012;**26**:55-8.
7. Murakami Y, Hoshi M, Imamura Y, Arioka Y, Yamamoto Y, Saito K. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases. *Mediators Inflamm.* 2013;2013.
8. Moet FJ, Meima A, Oskam L, Richardus JH. Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. *Lepr Rev.* 2004;**75**:310-32.
9. Douglas JT, Cellona RV, Fajardo TT Jr, Abalos RM, Balagon MV, Klaster PR. Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. *Clin Diag Lab Immunol.* 2004;**11**:897-900.
10. Becerra A, Warke RV, Xhaja K, Evans B, Evans J, Martin K *et al.* Increased activity of indoleamine 2, 3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function. *J Gen Virol.* 2009;**90**:810-7.
11. Rahfiludin MZ, Kartasurya MI, Purwaningsih E. The different levels of interferon gamma capacity production on several stages of leprosy. *Med J Indones.* 2007;**16**:224-7.
12. Harden JL, Egilmez NK. Indoleamine 2, 3-dioxygenase and dendritic cell tolerogenicity. *Immunol Invest.* 2012;**41**:738-64.
13. Muller AJ, Heseler K, Schmidt SP, Spekker K, Mackenzie CR, Däubener W. The missing link between indoleamine 2, 3-dioxygenase mediated antibacterial and immunoregulatory effects. *J Mol Med.* 2009;**13**:1125-35.
14. Njau F, Geffers R, Thalmann J, Haller H, Wagner AD. Restriction of Chlamydia pneumoniae replication in human dendritic cell by activation of indoleamine 2, 3-dioxygenase. *Microbes Infect.* 2009;**11**:1002-10.
15. King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxygenase. *Int J Biochem Cell Biol.* 2007;**39**:2167-72.



Journal of Pakistan Association of Dermatologists

Country [Pakistan](#) - SIR Ranking of Pakistan

10

Subject Area and Category [Medicine](#)
[Dermatology](#)

Publisher [Pakistan Association of Dermatologists](#)

H Index

Publication type [Journals](#)


ISSN [15609014](#)

Coverage [1999-ongoing](#)


[Homepage](#)

[Join the conversation about this journal](#)

Quartiles







SJR



Citations per document





← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scima
```


Journal of Pakistan Association of Dermatologists

[HOME](#) [ABOUT](#) [LOGIN](#) [REGISTER](#) [SEARCH](#) [CURRENT](#)
[ARCHIVES](#) [ANNOUNCEMENTS](#)

USER
Username
Password
 Remember Me

Home > Vol 28, No 2 (2018)

Journal of Pakistan Association of Dermatology

NOTIFICATION
[View](#)
[Subscribe](#)

The Journal of Pakistan Association of Dermatologists is the official journal the Pakistan. It is published quarterly, four issues per volume and one volume per year (ISSN 1560-9014). The journal is recognized by Pakistan Medical and Dental Council and is indexed in:


1. College of Physicians and Surgeons Pakistan MEDLIP
2. Ulrich's International Periodical Directory, USA
3. ExtraMED, London
4. EMBASE/Excerpta Medica, The Netherlands
5. Index Medicus, WHO Alexandria, Egypt.
6. Pak Medinet, Islamabad

JOURNAL CONTENT
Search
Search Scope

Browse
[By Issue](#)
[By Author](#)
[By Title](#)

FONT SIZE

INFORMATION
[For Review](#)
[For Author](#)
[For Librarian](#)



Indoleamine 2, 3-dioxygenase (IDO) levels in leprosy patients with positive serology

by Ago Harlim

Submission date: 17-Jul-2018 09:39AM (UTC+0700)

Submission ID: 983042524

File name: 1079-2193-2-PB.pdf (144.97K)

Word count: 2057

Character count: 11411

Indoleamine 2, 3-dioxygenase (IDO) levels in leprosy patients with positive serology

Ago Harlim, M. Zen Rahfiludin*

Faculty of Medicine, The Christian University of Indonesia, Jl. Mayjen Sutoyo, Cawang . Jakarta Timur (50275). Indonesia

* Faculty of Public Health, Diponegoro University, Indonesia
Jl. Prof. Soedarto, Sh. Tembalang, Semarang (50239). Indonesia

Abstract

Background Seropositive leprosy individuals have a tendency to experience change into leprosy lepromatous type. Previous studies have demonstrated that the activity of indoleamine 2, 3-dioxygenase (IDO) in patients with lepromatous type leprosy is higher than those with tuberculoid type leprosy. However, no study has been available showing how IDO level can be correlated to seropositive subjects.

Methods Our observational cross-sectional study was conducted in Brebes, Central Java, Indonesia. Leprosy seropositivity was determined by measuring the level of anti-phenolic glycolipid-1 IgM and IDO level using ELISA.

Results Result of The IDO level in seropositive leprosy subjects was higher compared to those who were seronegative ($p = 0.048$).

Conclusion In the early stage of leprosy infection, a high level of IDO level can already be found, therefore, it can affect immune response and ultimately affecting further course of the disease .

Key words

Seropositive leprosy, indoleamine 2, 3-dioxygenase, anti-phenolic glycolipid-1 IgM.

Introduction

Leprosy still remains a major public health problem in Indonesia since the incidence of leprosy is relatively high.¹ It is possibly due to contact with seropositive leprosy patients that have been turning into manifest leprosy.

Measuring the level of anti-phenolic glycolipid-1 immunoglobulin M (PGL-1 IgM) is one of the methods to detect seropositive leprosy subjects.^{2,3} The level of such cellular immune response will determine leprosy spectrum. The

cellular immunity in leprosy tuberculoid type is still good, on the contrary, there is decreased cellular immunity in leprosy lepromatous type.⁴ Individuals with seropositive leprosy contact (IgM anti-PGL-1 level more than 600 unit/ml), have a tendency to experience a change into leprosy lepromatous type.

Previous studies have demonstrated that leprosy patients with lepromatous type have a higher activity of indoleamine 2, 3-dioxygenase (IDO) compared to those with tuberculoid type. The role of IDO levels in leprosy has been studied and an increased number of macrophages/dendritic cells (DC-lineage IDO+ cells were found in lepromatous (LL) compared to tuberculoid (BT) and reversal reaction (RR) patients. LL lesions were characterized by

Address for correspondence

M. Zen Rahfiludin
Faculty of Public Health,
Universitas of Diponegoro, Jl. Prof Soedarto Sh,
Tembalang, Semarang, Indonesia
Email: rafiludin@yahoo.com

Short description of IDO and its effect on leprosy
131

massive macrophage infiltration containing a variable number of Virchow cells, full of bacilli accompanied by few lymphocytes, separated from the flat epidermis by a clear zone. BT lesions were characterized by an organized dermal granuloma composed of phagocytic cells with evident epithelioid differentiation surrounded by lymphocytes or giant cells. RR lesions showed activated macrophages with an epithelioid appearance, organized or not as granuloma.⁵

However, no study has been conducted to evaluate how IDO level can be correlated to seropositive leprosy subjects (IgM anti PGL-1 level more than 600 unit/ml) and have not showed a clinical manifestation on the skin. Our study aimed to identify the difference of IDO level between seropositive and seronegative leprosy subjects.

Methods

Our study was an observational study using a cross-sectional method. In August 2015, the study was conducted in Brebes, Central Java, Indonesia. Ethical clearance was approved by the Ethics Committee of Medical and Public Health Research, Faculty of Public Health, Diponegoro University.

The eligible subjects participated in our study were those who fulfilled the inclusion criteria: individuals who were living together with a leprosy patient, age between 15-55 years, showed no clinical symptom of leprosy, were not taking immunosuppressants during the last three months prior to the study and those who were willing to participate in our study. They also did not suffer from tuberculosis and did not take any anti-tuberculosis medications. The subjects were divided into 2 groups, i.e. those with seropositive leprosy (anti PGL-1 IgM >

600 unit/ml.) 6 and those who were seronegative.

Five milliliters of venous blood was drawn from each subject. The whole blood was centrifuged to separate the serum, which was then stored at -70°C. Seropositive leprosy was determined by measuring the levels of anti-PGL-1 IgM antibodies using enzyme-linked immunosorbent assay (ELISA) (Polyclonal rabbit anti-human IgM/HRP (Dako ®) and analyzing IDO levels using ELISA commercial kits (Cusabio®, Catalog No. CSB-E09966h). All tests were conducted at the Institute Tropical Disease Laboratory, Airlangga University, Surabaya.

The education level of subjects was categorized into 2 groups, i.e. basic and moderate education. Subjects in basic education group were those who had completed their elementary and junior high school, while moderate education group involved those with senior high school educational background.

Results

Table 1 shows that the gender, level of education and age had no effect on the seropositivity (anti-PGL-1 IgM antibodies levels) in leprosy patients, but the levels of IDO were significantly different between seropositive leprosy with seronegative subjects ($p = 0.048$).

In sex variable, there were 20.7% male and 79.3% female with seropositive leprosy and 33.3% male and 66.7% female with seronegative leprosy. There is no significant difference between seropositive leprosy subjects and seronegative leprosy subjects in sex variable ($p = 0.275$).

In level of education variable, seropositive leprosy subjects in primary education is 82.8% and 17.2% is in higher education while in

Table 1 Subject characteristics and indoleamine 2, 3-dioxygenase (IDO) levels.

| Variables | Seropositive leprosy (n = 29) | Seronegative leprosy (n = 30) | P |
|----------------------------|----------------------------------|----------------------------------|--------------------|
| Sex | | | |
| Male (%) | 20.7 | 33.3 | 0.275 ^a |
| Female (%) | 79.3 | 66.7 | |
| Level of education | | | |
| Primary education (%) | 82.8 | 80.0 | 0.786 ^a |
| Higher education (%) | 17.2 | 20.0 | |
| Age (years), (mean + SD) | 33 ± 10 | 35 ± 11 | 0.399 ^b |
| IDO (pg/mL), (median + SD) | 13.80 ± 9.13 | 9.10 ± 4.60 | 0.048 ^c |

a=chi-square test, b= independent t-test, c=Mann-Whitney test

seronegative leprosy subjects there were 80% in primary education and 20% in higher education ($p = 0.786$)

The mean age of seropositive leprosy subjects was 33 ± 10 years and the mean age of seronegative leprosy subjects was 35 ± 11 years ($p = 0.399$)

The mean IDO level in seropositive leprosy subject was 13.80 ± 9.13 pg/mL while that in seronegative leprosy subject was 9.10 ± 4.60 pg/mL. There was significant difference between seropositive leprosy and seronegative leprosy subjects in terms of IDO level ($p=0.048$).

Discussion

The first body mechanical defense against *Mycobacterium leprae* is by activating the antigen presenting cells (APCs) of immune system, i.e. the dendritic cells, monocytes and macrophages. IDO is predominantly expressed in APCs. Interferon gamma (IFN- γ) and dependent and/or independent signal pathways can activate and mediate IDO.⁷

Higher level of IDO found in seropositive leprosy subjects of our study supported the results of previous studies which indicate a high IDO protein expression in lepromatous skin lesions and high IDO activity in the sera of lepromatous leprosy patients.⁵ People who live

together under one and the same roof with leprosy patients with seropositive anti-PGL-I antibody have higher risk for developing leprosy (particularly the lepromatous type) compared to those who have contact with seronegative patients. The anti-PGL-I antibody level in people who live together under one and the same roof with leprosy indicates increased risk of having leprosy in the next 4 years. Another study in Philippines showed an increased risk of developing leprosy to 24-fold is caused by seropositive contacts.^{8,9}

In addition due to *M. leprae*, the increased IDO activity in the sera of lepromatous leprosy patients also depends on IFN- γ . There is also a statement that IDO activity was at least partially dependent upon IFN- γ from a study in dengue patients.¹⁰ IDO can be induced in response to various stimuli. The most potent inducer is IFN- γ , although other inflammatory stimuli, including type-I interferons (IFN- α/β) and bacterial lipopolysaccharide (LPS), and some viruses and intracellular pathogens, can induce IDO expression.¹¹ Support for the "two signal" requirement for IDO-expression is also been obtained in human samples.¹⁴ For example, human monocytes expressed IDO in lepromatous leprosy due to the synergistic actions of IFN- γ and the bacterium (likely through pattern recognition receptor signaling).⁵ *M. leprae* and IFN- γ is a cause of an increased of IDO expression in monocytes leprosy patients lepromatous type.⁵ Leprosy patients with clinical

manifestation of leprosy or those with seronegative leprosy have a less IFN- γ level than seropositive leprosy.¹¹

A higher IDO level in seropositive group found in our study supports the results of some previous studies, which showed that IDO induction after bacterial infection could be beneficial to the host. Amino acid tryptophan will break into stable metabolite called kynurenine when the IDO level increases.¹² Moreover, tryptophan depletion and starvation will occur since bacteria need tryptophan.^{13,14} The growth of bacteria is dependent on the greater amount of tryptophan rather than T cells.¹⁵

IDO could be considered to be a double-edged sword in the immune response against pathogens. Immune cells, including antigen-presenting cells like DCs, are able to express IDO in response to various stimuli.¹⁶

Acknowledgement

Our grateful thank to Prof. Indropo Agustini, MD, DV and Leprosy Study Group of Tropical Disease Centre for using the laboratory for IgM M anti-PGL-1 and IDO assay test at University of Airlangga, Surabaya, Indonesia and also to the technician of the Institute Tropical Disease (ITD) Laboratory, Iswayudi SKM; Dinar Adriaty, S.Si, M. Kes; Ratna Wahyuni S.Si, M. Kes who examined IgM anti-PGL-1 and IDO.

References

1. World Health Organization (WHO). Global leprosy update, 2013; reducing diseases burden. *Wkly Epidemiol Rec*. 2014;**89**:389-400.
2. Aguzi I, Adriaty D, Wahyuni R, Izumi S. Correlation between the sero-positivity level and new case detection rate (NCDR) in some leprosy endemic areas of Indonesia. *Jpn J Lepr*. 2009;**78**:140.

3. Izumi S. Subclinical infection by *Mycobacterium leprae*. *Int J Lepr*. 1999;**67** (4)(Suppl):S67-71.
4. Seollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. *Clin Microbiol Rev*. 2006;**19**:338-81.
5. de Souza Sales J, Lara FA, Amadeu TP, de Oliveira Fulco T, de Costa Nery JA, Sampaio EP *et al*. The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. *Clin Exp Immunol*. 2011;**165**:251-63.
6. Rahiludin MZ, Pangestuti DR. Phyllanthus niruri extract could improve immunoglobulin-M anti phenolic glycolipid-1 level in seropositive contact of Hansen's disease patients. *J Health Res*. 2012;**26**:55-8.
7. Murakami Y, Hoshi M, Imamura Y, Arioka Y, Yamamoto Y, Saito K. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases. *Mediators Inflamm*. 2013;2013.
8. Most FJ, Meima A, Oskam L, Richardus JH. Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. *Lepr Rev*. 2004;**75**:310-32.
9. Douglas JT, Cellona RV, Fajardo TT Jr, Abalos RM, Balagon MV, Klaster PR. Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. *Clin Diag Lab Immunol*. 2004;**11**:897-900.
10. Becerra A, Warke RV, Khaja K, Evans B, Evans J, Martin K *et al*. Increased activity of indoleamine 2, 3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function. *J Gen Virol*. 2009;**90**:810-7.
11. Rahiludin MZ, Kartasurya MI, Purwaningsih E. The different levels of interferon gamma capacity production on several stages of leprosy. *Med J Indones*. 2007;**16**:224-7.
12. Harden JL, Egilmez NK. Indoleamine 2, 3-dioxygenase and dendritic cell tolerogenicity. *Immunol Invest*. 2012;**41**:738-64.
13. Muller AJ, Heseler K, Schmidt SP, Spekker K, Mackenzie CR, Daubener W. The missing link between indoleamine 2, 3-dioxygenase mediated antibacterial and immunoregulatory effects. *J Mol Med*. 2009;**13**:1125-35.
14. Njau F, Geffers R, Thalmann J, Haller H, Wagner AD. Restriction of *Chlamydia pneumoniae* replication in human dendritic cell by activation of indoleamine 2, 3-dioxygenase. *Microbes Infect*. 2009;**11**:1002-10.
15. King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxygenase. *Int J Biochem Cell Biol*. 2007;**39**:2167-72.

Indoleamine 2, 3-dioxygenase (IDO) levels in leprosy patients with positive serology

ORIGINALITY REPORT

26%

SIMILARITY INDEX

13%

INTERNET SOURCES

24%

PUBLICATIONS

2%

STUDENT PAPERS

PRIMARY SOURCES

- 1 J. de Souza Sales. "The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression : IDO is involved in immunosuppression during lepromatous leprosy", *Clinical & Experimental Immunology*, 08/2011
Publication 6%
- 2 vir.sgmjournals.org
Internet Source 4%
- 3 tci-thaijo.org
Internet Source 4%
- 4 Harden, Jamie L, and Nejat K Egilmez. "Indoleamine 2,3-Dioxygenase and Dendritic Cell Tolerogenicity", *Immunological Investigations*, 2012.
Publication 3%
- 5 leprosy-portal.org
Internet Source 2%

Mohammad Taraz, Somayeh Niknam, Amir

- 6 Houshang Ehsani. "Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies", *Dermatologic Therapy*, 2017
Publication 1%

- 7 Mohammad Z. Rahfiludin, Praba Ginandjar, Dina R. Pangestuti. "Correlation of zinc plasma and IgM anti-PGL-1 levels among close contact of leprosy", *Medical Journal of Indonesia*, 2012
Publication 1%

- 8 ejournal.undip.ac.id
Internet Source 1%

- 9 *Molecular and Integrative Toxicology*, 2015.
Publication 1%

- 10 Düppre, Nádia C., Luiz Antonio B. Camacho, Anna M. Sales, Ximena Illarramendi, José Augusto C. Nery, Elizabeth P. Sampaio, Euzenir N. Sarno, and Samira Bühner-Sékula. "Impact of PGL-I Seropositivity on the Protective Effect of BCG Vaccination among Leprosy Contacts: A Cohort Study", *PLoS Neglected Tropical Diseases*, 2012.
Publication 1%

- 11 www.kccp.or.kr
Internet Source 1%

- 12 Praba Ginandjar, Lintang Dian Saraswati, 1%

Bagoes Widjanarko. "Profile of glycated-hemoglobin, antioxidant vitamin and cytokine levels in pulmonary tuberculosis patients: A cross sectional study at Pulmonary Diseases Center Semarang City, Indonesia", Biomedical Journal, 2016

Publication

13

www.jpapad.com.pk

Internet Source

1%

Exclude quotes On

Exclude matches < 1%

Exclude bibliography On

Bagoes Widjanarko. "Profile of glycated-hemoglobin, antioxidant vitamin and cytokine levels in pulmonary tuberculosis patients: A cross sectional study at Pulmonary Diseases Center Semarang City, Indonesia", Biomedical Journal, 2016

Publication

13

www.jpap.com.pk

Internet Source

1%

Exclude quotes On

Exclude matches < 1%

Exclude bibliography On